<DOC>
	<DOCNO>NCT01870297</DOCNO>
	<brief_summary>The main purpose study assess safety tolerability LY3025876 give alone ( Part A ) combination liraglutide ( Part B ) participant type 2 diabetes mellitus ( T2DM ) .</brief_summary>
	<brief_title>A Study LY3025876 Participants With Diabetes</brief_title>
	<detailed_description>This study also evaluate much study drug enters blood stream long take body remove study drug . Information side effect may occur also collect . Participants continue usual diet exercise program may remain physician-prescribed dose metformin . Each part study expect last 10 12 week average , include screen . Participants may enroll one part .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Diagnosis type 2 diabetes mellitus ( T2DM ) determine investigator , control diet exercise alone stable dose metformin least 30 day Have body mass index ( BMI ) great equal 23 less equal 45 kilogram per square meter ( kg/m^2 ) screening Have supine blood pressure read screen 90160 millimeter mercury ( mmHg ) ( systolic ) 4095 mmHg ( diastolic ) Women childbearing potential due surgical sterilization ( hysterectomy bilateral oophorectomy tubal ligation ) menopause Have take LY3025876 investigational drug like ( example , fibroblast growth factor21 [ FGF21 ] relate drug ) know allergy drug History presence bone disease ( include osteoporosis unhealed fracture ) Current active treatment periodontal disease Have significant change weight , define gain loss least 4 kilogram ( kg ) ( 9 pound ) last 3 month Have great 1 episode severe hypoglycemia within 6 month screen require assistance another person actively administer carbohydrate , glucagon , resuscitative action seizure coma Have know allergy history intolerance liraglutide , glucagonlike peptide 1 ( GLP1 ) analogue , relate compound Have history acute chronic pancreatitis Have personal family history medullary thyroid carcinoma multiple endocrine neoplasia syndrome type 2</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>